Rhythm Pharmaceuticals, Inc.(RYTM) Stock Research - Grey Stern Research

Rhythm Pharmaceuticals, Inc. (RYTM) Stock Analysis

$60.08 (-1.25%)

RYTM Financial Performance


Use the table below to view Rhythm Pharmaceuticals, Inc.'s financial profile. This data is gathers from the latest available financial statements. Annual data is taken from the trailing 12 months of statements. All numbers are reported in US Dollars and so any foreign currencies are converted to USD so comparison's can be done.

Based on Financial Statements from Q3 - 2024

Metric Value Ranking among Peers
Price $60.08 -
52 Week Low $34.17 -
52 Week High $68.58 -
Market Cap $3.7 Billion 5/20
Gross Margin 88% 7/20
Profit Margin -100% 13/20
EBITDA margin -132% 13/20
Q3 - 2024 Revenue $33.3 Million 3/20
Q3 - 2024 Earnings -$45.0 Million 11/20
Q3 - 2024 Free Cash Flow $14.8 Million 2/20
Trailing 4 Quarters Revenue $112.5 Million 5/20
Trailing 4 Quarters Earnings -$260.2 Million 14/20
Quarterly Earnings Growth -2% 10/20
Annual Earnings Growth -41% 15/20
Quarterly Revenue Growth 48% 6/20
Annual Revenue Growth 40% 6/20
Cash On Hand $47.5 Million 18/20
Short Term Debt $0 18/20
Long Term Debt $4.0 Million 14/20

Rhythm Pharmaceuticals, Inc. Financial Metrics


Financial metrics are a set of useful numbers that can give key performance indicators of a company. The various metrics can include information about profitability, growth, and debt load. When combined and use properly they can tell an analyst a compelling fact-based story of how the company is currently performing. To compare Rhythm Pharmaceuticals, Inc.'s metrics versus it's peers make sure to run our peer analysis tool.

Valuation Metrics

Metric Value Ranking among Peers
PE -1.00 2/20
PS 32.81 9/20
PB 24.18 1/20
PC 77.70 1/20
Liabilities to Equity 18.80 1/20
ROA -0.72 20/20
ROE -23.20 20/20
Current Ratio 1.72 18/20
Quick Ratio 1.42 16/20
Long Term Debt to Equity 0.36 3/20
Debt to Equity 0.36 3/20
Burn Rate 1.05 18/20
Cash to Cap 0.01 20/20
CCR -0.33 19/20
EV to EBITDA -83.15 18/20
EV to Revenue 32.43 7/20

Company Details

Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of rare genetic diseases of obesity. The company's lead product candidate is IMCIVREE, a potent melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome. It is also developing setmelanotide, which is in Phase II clinical trials for treating POMC or LEPR heterozygous deficiency obesities, steroid receptor coactivator 1 deficiency obesity, SH2B1 deficiency obesity, MC4 receptor deficiency obesity, Smith-Magenis syndrome obesity, POMC epigenetic disorders, and other MC4R disorders. Rhythm Pharmaceuticals, Inc. has a collaborative research agreement with the Clinical Registry Investigating Bardet-Biedl Syndrome. The company was formerly known as Rhythm Metabolic, Inc. and changed its name to Rhythm Pharmaceuticals, Inc. in October 2015. Rhythm Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.

CEO: Mr. Hunter Smith

Website: https://www.rhythmtx.com

Address: 222 Berkeley St Fl 12 Boston, MASSACHUSETTS

Exchange: NASDAQ Global Market

Industry: Biotechnology

Rhythm Pharmaceuticals, Inc. Peer Analysis


A useful and more reliable way of seeing the health of a company is to compare it to other companies operating in the same sector. Below is our list of companies which we rank are the closest peers to Rhythm Pharmaceuticals, Inc.. If you feel that peers should be added or removed from this list please contact us. To run an in-depth peer analysis which compares many financial metrics click on the link below.

Stock Ticker Market Cap
Solid Biosciences Inc. SLDB $207.0 Million
Protagonist Therapeutics, Inc. PTGX $2.5 Billion
uniQure N.V. QURE $312.4 Million
Syndax Pharmaceuticals, Inc. SNDX $1.4 Billion
Rocket Pharmaceuticals, Inc. RCKT $1.2 Billion
Arvinas, Inc. ARVN $1.7 Billion
Kiniksa Pharmaceuticals, Ltd. KNSA $1.5 Billion
MeiraGTx Holdings plc MGTX $488.5 Million
Stoke Therapeutics, Inc. STOK $605.4 Million
Revolution Medicines, Inc. RVMD $8.1 Billion
Black Diamond Therapeutics, Inc. BDTX $139.8 Million
Pliant Therapeutics, Inc. PLRX $890.3 Million
Avidity Biosciences, Inc. RNA $4.6 Billion
Relay Therapeutics, Inc. RLAY $734.8 Million
Inozyme Pharma, Inc. INZY $168.3 Million
Viridian Therapeutics, Inc. VRDN $1.6 Billion
Nuvalent, Inc. NUVL $6.7 Billion
Arcellx, Inc. ACLX $4.8 Billion
Ventyx Biosciences, Inc. VTYX $173.2 Million
Run Peer Analysis
Income Statement
Balance Sheet
Cash Flow Statement
RYTM Income Statements
Quarter Year Revenue Earnings
Q3 2024 $ 33.3 Million -$45.0 Million
Q2 2024 $ 29.1 Million -$32.3 Million
Q1 2024 $ 26.0 Million -$141.4 Million
Q4 2023 $ 24.2 Million -$41.6 Million
Q3 2023 $ 22.5 Million -$44.2 Million
Q2 2023 $ 19.2 Million -$46.7 Million
Q1 2023 $ 11.5 Million -$51.8 Million
Q4 2022 $ 8.8 Million -$42.9 Million

View All

RYTM Balance Sheets
Quarter Year Cash & Equivalents Total Assets Total Debt Total Equity
Q3 2024 $47.5 Million $363.6 Million $4.0 Million $11.2 Million
Q2 2024 $161.7 Million $381.8 Million $252.6 Million $39.3 Million
Q1 2024 $53.4 Million $258.7 Million $108.4 Million $61.6 Million
Q4 2023 $60.1 Million $332.7 Million $1.3 Million $169.8 Million
Q3 2023 $64.6 Million $354.2 Million $1.4 Million $197.5 Million
Q2 2023 $115.7 Million $309.9 Million $1.6 Million $182.3 Million
Q1 2023 $109.7 Million $345.7 Million $1.8 Million $219.8 Million
Q4 2022 $127.7 Million $382.5 Million $1.9 Million $264.3 Million

View All

RYTM Cash Flow Statements
Quarter Year freeCashFlow capitalExpenditure netChangeInCash
Q3 2024 $14.8 Million $40.0 Million -$113.7 Million
Q2 2024 -$29.1 Million $0 $108.2 Million
Q1 2024 -$80.7 Million -$40.0 Million -$6.7 Million
Q4 2023 -$29.4 Million $1,000 -$4.5 Million
Q3 2023 $0 $0 $0
Q2 2023 $0 $0 $0
Q1 2023 -$36.5 Million -$47,000 -$18.0 Million
Q4 2022 -$30.0 Million $4.0 Million -$57.4 Million

View All

Cookies

We use cookies to offer a better browsing experience. Cookies enhance site navigation, analyze site usage, and assist in our marketing efforts. By clicking Accept. you agree to the storing of cookies on your device. To refuse all non-required cookies, click on Decline.

Accept View Terms & Conditions